Menu

Biosimilars/General

02 AA010638

Ten best-selling biosimilars in Brazil in 2023

Biosimilars/General | Posted 01/10/2024

Biosimilars experienced a notable increase in sales during 2023, according to a study published by the Brazilian Association of Generic and Biosimilar Drug Industries (PróGenéricos). The data reveal that about 892,000 units of biosimilars were sold, representing a 43% growth compared to 2022.

China-flag

International biosimilars players expanding their presence in China

Biosimilars/General | Posted 18/09/2024

The market for copy biologicals in China has significantly grown over the past decade. By early 2022, over 60 pharmaceutical companies were involved in the development of copy biological products [1].

Adalimumab 2 V14A10

Boehringer and GoodRx make Humira biosimilar available at 92% discount

Biosimilars/General | Posted 10/09/2024

On 18 July 2024, it was announced that Boehringer Ingelheim (Boehringer) and GoodRx, the leading prescription savings platform in the US, launched a patient affordability initiative. From now on, Boehringer's citrate-free adalimumab-adbm, a biosimilar to Humira (adalimumab), will be available at a 92% discount to the list price of the AbbVie originator drug, exclusively on GoodRx.

Health Canada Logo V14A31

Biosimilars approved in Canada

Biosimilars/General | Posted 31/01/2014

Last update: 6 August  2024

In Canada, the regulatory body for the approval of biologicals is the Biologics and Genetic Therapies Directorate (BGTD) of the Health Products and Food Branch (HPFB) of Health Canada.

20 AA010933

Humira's resilience in the face of biosimilar competition

Biosimilars/General | Posted 30/07/2024

AbbVie’s Humira (adalimumab) has retained more than 80% of patients in the last year (Q3/2023 to Q2/2024), despite the availability of nine lower-priced rival products available in the US. This raises questions among drug pricing experts and analysts about whether the market for prescription biosimilars can survive in its current form.

FDA V17F30

Biosimilars approved in the US

Biosimilars/General | Posted 14/08/2015

Last update: 23 July 2024

In the US, a legal framework for approving biosimilars was established in 2009, via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).

Biosimilars V13E10

Biosimilars approved in Europe

Biosimilars/General | Posted 08/07/2011

Last update: 16 July 2024

In the European Union (EU), a legal framework for approving biosimilars was established in 2003. This framework means that biosimilars can only be approved centrally via the European Medicines Agency (EMA) and not nationally.

Discount Save money V15c13

Boehringer Ingelheim to expand access to adalimumab biosimilar

Biosimilars/General | Posted 03/07/2024

On 13 May 2024, Boehringer Ingelheim (Boehringer) announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s biosimilar to AbbVie’s Humira (adalimumab) in the US.

Application V15a16

Challenges and progress in the registration of biosimilars in Latin America

Biosimilars/General | Posted 25/06/2024

Biosimilar medicines offer an effective and economical alternative to biotechnological medicines, with a rapidly expanding global market. However, Latin America still faces several significant challenges. The obstacles and advancements experienced in recent years are detailed below.

19646665_l

Canada's path to biosimilar adoption and healthcare accessibility: insights from British Columbia

Biosimilars/General | Posted 19/06/2024

Canada’s British Columbia transitioned to biosimilars in November 2019, achieving significant cost savings reinvested in BC PharmaCare. This initiative has improved drug coverage, expanding access to various medications and medical devices.